本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Immunovant, Inc.

21.65
-0.3300-1.50%
盘后22.661.01+4.67%19:59 EDT
成交量:144.01万
成交额:3,125.76万
市值:37.74亿
市盈率:-7.64
高:22.14
开:22.00
低:21.34
收:21.98
52周最高:32.10
52周最低:12.72
股本:1.74亿
流通股本:6,698.10万
量比:0.82
换手率:2.15%
股息:- -
股息率:- -
每股收益(TTM):-2.8352
每股收益(LYR):-2.7303
净资产收益率:-77.58%
总资产收益率:-47.07%
市净率:6.20
市盈率(LYR):-7.93

数据加载中...

2023/12/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/28

重要事件披露

Form 8-K - Current report
2023/11/09

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/09

重要事件披露

Form 8-K - Current report
2023/10/05

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/09/29

重要事件披露

Form 8-K - Current report
2023/09/28

[补充]招股说明书

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2023/09/27

[补充]招股说明书

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2023/09/26

重要事件披露

Form 8-K - Current report
2023/08/23

重要事件披露

Form 8-K - Current report
2023/08/10

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/08/10

重要事件披露

Form 8-K - Current report
2023/05/22

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2023/05/22

重要事件披露

Form 8-K - Current report
2023/04/05

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2023/03/27

重要事件披露

8-K - Current report
2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/03

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans